This is in fact a small molecule inhibitor of the apical sodium-dependent bile acid transporter (ASBT), also known as ileal bile acid transporter (IBAT), the first drug approved in the EU for the treatment of PFIC while is used worldwide also in Alagille syndrome and biliary atresia [143]. Here, SLC10A2 is linked to progressive familial intrahepatic cholestasis.